Wednesday's Watchlist: 6 Reasons Why NYSE American (NNVC) Has Serious Breakout Potential

Breaking...

*Sponsored Wednesday's Watchlist: 6 Reasons Why NYSE American (NNVC) Has Serious Breakout Potential February 5th Greetings, Friend! Breaking... We've identified a new breakout idea currently on the NYSE American. So, what's special about this one? This is a low float idea. Registering fewer than 14Mn shares in its float, volatility potential could be extremely present. Could that be part of the reason as to why this profile was able to complete a 250% move during the past 12 month period? With an aim to disrupt multiple, Bn dollar markets, this company has eluded Wall Street's attention for the time being. But for how much longer, that's tough to say. As this company powers forward in 2025 and beyond, it may just be a matter of time until they become a household name as global health uncertainties could propel their game-changing work into the spotlight. Hitting #1 on my watchlist this week, it may be time to consider this breakout idea for your radar: NanoViricides, Inc. (NYSE American: NNVC). NanoViricides, Inc. is a global leader in the development of nanomedicine drugs. Their unique nanoviricide® platform technology defines a novel mechanism enabling first-in class drugs against vir-uses. A nanoviricide is designed to specifically attack enveloped vir-us particles, on the same sites that they use to bind to cells, and dismantle them, blocking reinfection cycle, going beyond what antibodies and immunotherapeutics do. It can also be designed to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity.  The company's unique biomimetic approach enables creation of drugs that a vir-us would be highly unlikely to escape due to mutations. NanoViricides is one of the few biopharma companies with its own multi-kilogram-scale c-GMP capable manufacturing facility for the drug substance as well as drug product. This facility is fully owned by the Company with no mortgage and is a major asset. This flexible, multi-product pilot plant can supply drug product for all of their programs through human clinical trials. Their cGMP manufacturing ability enables substantial time and cost savings in their drug development programs. Further, it is capable of production for initial marketing, enabling early revenues upon drug approval, of about $100Mn~$500Mn per year. Company Sources: Presentation. Website. As for why someone might want to pay attention to NanoViricides, Inc. (NYSE American: NNVC) right now, here's 6 immediate reasons... #1. Innovative technology: Their nanoviricide technology could potentially offer a new approach to treating viral infections. A nanoviricide is created by chemically attaching a vir-us-binding ligand, derived from the binding site of the vir-us on its cell surface receptor, to a nanomicelle flexible polymer. This binding site does not change significantly when a vir-us mutates. Tailor-made design and selection of (1) the vir-us-binding ligand; and (2) the backbone "nanomicelle," separately, allows the company to rapidly optimize drug candidates (a) against a number of vir-uses, (b) for desired pharmacokinetic characteristics (e.g. sustained effect), and (c) for different routes of administration. This versatility is unmatched in the industry. #2. Broad application: Their platform could potentially be adapted to target various vir-uses, which might be particularly relevant in a post-CV19 world. #3. Potential market: If successful, their products could address significant unmet medical needs in antiviral treatments. #4. Low float: With a float of approximately 13.97Mn shares, volatility potential could be significant on a daily basis. #5. NanoViricides Engages CRO for Phase II Clinical Trial: Company president, Anil R. Diwan, Ph.D., shared: "NV-387, our broad-spectrum antiviral drug is poised to cause a revolution in treatment of viral diseases, just as antibiotics revolutionized the treatment of bacterial diseases. Our regulatory development strategy for this drug is now further advancing into a Phase II clinical trial stage." #6. Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals: President Diwan also shared: NV-387 stands apart in the field of antiviral countermeasures in that escape of vir-us even as it evolves is highly unlikely. This is because (i) NV-387 mimics the essential host-side feature that the vir-us requires for causing infection, and (ii) the activity spectrum of NV-387 is so broad, encompassing not just a type of vir-us, but across many different types of vir-uses, that any small changes in a vir-us would be unlikely to enable the vir-us to escape NV-387. ----- Coverage is officially initiated on NanoViricides, Inc. (NYSE American: NNVC). If there are any updates necessary, I'll have them out to you quickly. Talk again shortly. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice